Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?

Ferrero, Simone; Dreyling, Martin

doi:10.3324/haematol.2017.167627

Cited by 21 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated that rituximab maintenance can improve survival after SCT. MRD assessment in MCL has not been systematically implemented in clinical practice; however, a few studies have shown the critical clinical significance of MRD‐positive disease status and risk of predicting future relapses . Another issue for MRD assessment in MCL is optimization of the technique according to the tissue type used to test MRD, as not all patients have bone marrow involvement at diagnosis and not all patients have peripheral blood lymphocytosis sufficient enough for testing MRD by either flow cytometry or PCR (allele specific quantitative oligonucleotide polymerase chain reaction).…”

Section: Advances In the Treatment Of MCLmentioning

confidence: 99%

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

2019

View full text Add to dashboard Cite

Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years. Heterogeneity in the clinical course of MCL—indolent vs aggressive—is further delineated by a correlation with the mutational status of the variable region of immunoglobulin heavy chain, methylation status, and SOX‐11 expression. Cyclin‐D1 negative MCL, in situ MCL neoplasia, and impact of the karyotype on prognosis are distinguished. Apart from Ki‐67% and morphology pattern (classic vs blastoid/pleomorphic), the proliferation gene signature has helped to further refine prognostication. Studies focusing on mutational dynamics and clonal evolution on Bruton's tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib) and/or Bcl2 antagonists (venetoclax) have further clarified the prognostic impact of somatic mutations in TP53, BIRC3, CDKN2A, MAP3K14, NOTCH2, NSD2, and SMARCA4 genes. In therapy, long‐term follow‐up on chemo‐immunotherapy studies has demonstrated durable remissions in some patients; however, long‐term toxicities, especially from second cancers, are a serious concern with chemotherapy. The therapeutic options in MCL are constantly evolving, with dramatic responses from nonchemotherapeutic agents (ibrutinib, acalabrutinib, and venetoclax). Chimeric antigen receptor therapy and combinations of nonchemotherapeutic agents are actively being studied and our focus is shifting toward making the treatment of MCL chemotherapy‐free. Still, MCL remains incurable. The following aspects of MCL continue to pose a challenge: disease transformation, role of the cytokine‐microenvironmental milieu, incorporation of positron emission tomography‐computerized tomography imaging, minimal residual disease in the prognosis, circulating tumor DNA testing for clonal evolution, predicting resistance to BTK inhibitors, and optimal management of patients who progress on BTK/Bcl2 inhibitors. Next‐generation clinical trials should incorporate nonchemotherapeutic agents and personalize the treatment based upon the genomic profile of individual patient. Recent advances in the field of MCL are reviewed.

show abstract

Section: Advances In the Treatment Of MCLmentioning

confidence: 99%

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

2019

View full text Add to dashboard Cite

show abstract

“…10 , 11 Of note, the National Comprehensive Cancer Network (NCCN) recommends that all recipients of aggressive therapy undergo consolidation therapy with HDT/ASCR, even after achieving complete response. 8 Faced with all of these different treatment options, factors such as minimal residual disease (a strong predictor of PFS), 12 a patient's age and frailty, and the clinical course of the disease (ie, indolent versus aggressive disease) can be useful in guiding the choice of regimen. 8 , 13 , 14 However, despite available CIT options, most patients relapse or become refractory (R/R) to treatment and therefore require > 1 line of therapy (LOT).…”

Section: Introductionmentioning

confidence: 99%

Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study

Ghosh

Émond

Lafeuille

et al. 2021

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: This study assessed treatment patterns in patients with mantle cell lymphoma (MCL) and compared health care resource utilization (HRU) and costs of ibrutinib with or without rituximab (I ± R) versus chemoimmunotherapy (CIT) in patients with relapsed/refractory MCL.Methods: For this retrospective cohort study, adults with MCL observed between May 13, 2013, and June 30, 2019, were identified using Optum's de-identified Clinformatics Data Mart Database. Treatment patterns were described among patients who received ≥1 line of therapy (LOT). HRU and costs (payer's perspective) were compared between patients treated with I ± R and CIT in the second or later line (2L + ) of therapy. To account for differences in baseline characteristics between the 2 cohorts, inverse probability of treatment weighting was used. Monthly HRU and costs starting from I ± R or CIT treatment initiation (index date) were compared during the first Oncology Care Model (OCM) episode (ie, first 6 months) postindex and during the observed duration of I ± R or CIT LOT (index LOT) using rate ratios (RRs) and mean monthly cost differences (MMCDs), respectively.Findings: Among 1346 patients with ≥1 LOT (median follow-up, 15.3 months), 870 (64.6%) were treated with CIT in the first line. Only 348 (25.9%) had a 2L of therapy, of whom 110 (31.6%) were treated with CIT and 98 (28.2%) with an ibrutinibbased therapy. A total of 300 patients were included for the comparison of HRU and costs between 2L +

show abstract

“…Within qPCR is the allele-specific oligonucleotide quantitative PCR (ASO-qPCR), in which the Ig complementarity-determining region is used to generate the patient-specific primers and probes [ 19 , 35 ]. By doing so, it reveals the distinctiveness of each patient at a sensitivity of 10 -4 to 10 -6 [ 36 ].…”

Section: Current Status Of Mrd Detection In Mantle Cell Lymphomamentioning

confidence: 99%

Advances in the assessment of minimal residual disease in mantle cell lymphoma

et al. 2020

View full text Add to dashboard Cite

The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lymphoma is still evolving but has great impact in determining the prognosis. Flow cytometry and polymerase chain reaction-based testing are most commonly used methods in practice; however, these methods are not sensitive enough to detect the dynamic changes that underline lymphoma progression. Newer methods using next-generation sequencing, such as ClonoSeq, are being incorporated in clinical trials. Other techniques under evolution include CAPP-seq and anchored multiplex polymerase chain reaction-based methods. This review article aims to provide a comprehensive update on the status of minimal residual disease detection and its prognostic effect in mantle cell patients. The role of circulating tumor DNA-based minimal residual disease detection in lymphomas is also discussed.

show abstract

Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?

Cited by 21 publications

References 21 publications

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study

Advances in the assessment of minimal residual disease in mantle cell lymphoma

Contact Info

Product

Resources

About